risperidone has been researched along with dronabinol in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (58.33) | 29.6817 |
| 2010's | 5 (41.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Gao, F; Lombardo, F; Obach, RS; Shalaeva, MY | 2 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Mowrey, DD; Sun, T; Tang, P; Tillman, TS; Wells, MM; Xu, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Egashira, N; Fujiwara, M; Iwasaki, K; Mishima, K; Mizuki, A; Nagai, H; Nishimura, R; Ogata, A; Sano, K; Shoyama, Y | 1 |
| Arnold, JC; Boucher, AA; Brzozowska, NI; Callaghan, PD; de Tonnerre, EJ; Kuligowski, M; Li, KM; Wang, XS; Wong, A | 1 |
1 review(s) available for risperidone and dronabinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
11 other study(ies) available for risperidone and dronabinol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Prediction of volume of distribution values in humans for neutral and basic drugs using physicochemical measurements and plasma protein binding data.
Topics: Blood Proteins; Chemical Phenomena; Chemistry, Physical; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding | 2002 |
Prediction of human volume of distribution values for neutral and basic drugs. 2. Extended data set and leave-class-out statistics.
Topics: Algorithms; Blood Proteins; Half-Life; Humans; Hydrogen-Ion Concentration; Models, Biological; Pharmaceutical Preparations; Pharmacokinetics; Protein Binding; Statistics as Topic; Tissue Distribution | 2004 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
Ensemble-based virtual screening for cannabinoid-like potentiators of the human glycine receptor α1 for the treatment of pain.
Topics: Analgesics, Non-Narcotic; Animals; Binding Sites; Cannabinoids; Drug Evaluation, Preclinical; Female; Lipids; Molecular Dynamics Simulation; Molecular Targeted Therapy; Nuclear Magnetic Resonance, Biomolecular; Oocytes; Pain; Protein Conformation; Protein Structure, Tertiary; Receptors, Glycine; Reproducibility of Results; Xenopus laevis | 2015 |
Antipsychotics improve Delta9-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice.
Topics: Acoustic Stimulation; Animals; Antipsychotic Agents; Dopamine; Dronabinol; Haloperidol; Inhibition, Psychological; Male; Mice; Nucleus Accumbens; Piperidines; Prefrontal Cortex; Pyrazoles; Reflex, Startle; Rimonabant; Risperidone; Rotarod Performance Test | 2006 |
The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions.
Topics: Animals; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Clozapine; Dose-Response Relationship, Drug; Dronabinol; Gene Expression Regulation; Locomotion; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Protein Binding; Proto-Oncogene Proteins c-fos; Raclopride; Receptor, Serotonin, 5-HT2A; Receptors, Dopamine D2; Reflex, Startle; Risperidone; Time Factors; Tritium | 2017 |